secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001628280-26-007715
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen Q3 FY2026 net loss $18.9M; PALISADE-4 topline expected H1 2026
-----------------------------------------------------------------------

- Net loss $18.9M for quarter ended Dec 31, 2025, vs $14.1M a year ago; R&D expense $14.2M, G&A $5.6M.
- Cash and equivalents $61.8M as of Dec 31, 2025; company targeting disciplined capital allocation.
- PALISADE-4 Phase 3 trial of fasedienol for social anxiety ongoing; topline results from randomized portion expected H1 2026.
- Previous PALISADE-3 Phase 3 missed primary endpoint in Dec 2025; safety data favorable.
- Appointed Nick Tressler as CFO in Dec 2025; refisolone IND submission for hot flashes planned H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026007715/0001628280-26-007715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026007715/vtgn-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-007715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer